Description
Eloha Vol.02 is a stabilized hyaluronic acid- (HA)-based filler with a hybrid structure. An innovative and patented “R Square” technology is used in the manufacture of Eloha fillers. It is a three-step technology, which includes the following stages: combining the mono- and biphasic HA gel particles together, rotation and mixing of the both types of particles, and obtaining the gel with a multilayer structure, i.e. biphasic particles inside of monophasic HA particles (“2 in 1 structure”). The ratio of mono- and biphasic HA in Eloha Vol.02 is 4 to 6. Such a multilayer structure of Eloha fillers allow their even distribution in the dermal layers: the particles tend to occupy as much space as possible leaving no free space, which results in a natural-looking effect.
Strengths of Eloha:
- the first HA filler with a multilayer biphasic-monophasic structure
- long-lasting and natural-looking esthetic effect due to the special “R Square” technology of Eloha filler production
- multilayer gel structure ensures maximum and even distribution of the filler in the dermal layers
- the filler is naturally degraded and eliminated from the body
- no filler migration to adjacent tissues
- the Eloha series contains three products varying in the ratio of monophasic HA to biphasic HA depending on the scope of use
Eloha Vol.02 is ideal for correction of moderately pronounced to deep facial wrinkles and folds, as well as facial contouring and lip augmentation. The filler is injected into the middle and deep dermis layers.
Scope of Eloha Vol.02:
- correction of moderate-to-severe wrinkles and folds (nasolabial fold, forehead and frown lines, mental crease, neck lines, and perioral wrinkles)
- lip contouring and augmentation
- jawline correction
- cheek correction (cheekbone volumization)
The aesthetic effect lasts from 9 to 12 months.
Product composition: HA 20 mg/ml, Lidocaine 0.3%
Eloha Vol.02
1 syringe × 1.0 ml, 2 needles per pack
Needle size: 27G
Manufacturer: DERMAFIRM Co., Ltd., South Korea
